Supplementary Table 2. Grade 3/4 adverse events that occurred in ≥2% of patients

Reported event terms were coded using MedDRA dictionary version 15.0. At each level of summarization, a patient was counted once for the most severe event if the patient reported one or more events. AEs defined according to National Cancer Institute Common Terminology Criteria for Adverse Events version 3.0.

	15 mg bid N=3 n (%)	30 mg bid N=7 n (%)	60 mg bid N=10 n (%)	120 mg bid N=7 n (%)	50 mg bid N=25 n (%)	100 mg qd N=7 n (%)	70 mg qd N=5 n (%)	90 mg qd N=19 n (%)	Total N=83 n (%)
Number of patients with at least 1 grade 3/4 AE	2 (66.7)	1 (14.3)	3 (30.0)	6 (85.7)	14 (56.0)	2 (28.6)	2 (40.0)	15 (78.9)	45 (54.2)
Aspartate aminotransferase increased	1 (33.3)	0	0	3 (42.9)	3 (12.0)	0	0	1 (5.3)	8 (9.6)
Fatigue	0	0	0	0	2 (8.0)	1 (14.3)	1 (20.0)	2 (10.5)	6 (7.2)
Gamma-glutamyltransferase increased	0	0	0	1 (14.3)	5 (20.0)	0	0	0	6 (7.2)
Alanine aminotransferase increased	0	0	0	3 (42.9)	1 (4.0)	0	0	2 (10.5)	6 (7.2)
Decreased appetite	1 (33.3)	0	0	2 (28.6)	1 (4.0)	0	0	0	4 (4.8)
Hypokalemia	0	1 (14.3)	0	1 (14.3)	1 (4.0)	0	0	1 (5.3)	4 (4.8)
Asthenia	0	0	0	0	2 (8.0)	0	0	1 (5.3)	3 (3.6)
Blood alkaline phosphatase increased	0	0	0	0	1 (4.0)	0	1 (20.0)	1 (5.3)	3 (3.6)
Blood bilirubin increased	0	0	0	0	0	0	1 (20.0)	2 (10.5)	3 (3.6)
Hyponatremia	0	0	0	0	3 (12.0)	0	0	0	3 (3.6)
Lymphopenia	0	0	0	0	1 (4.0)	0	0	2 (10.5)	3 (3.6)
Nausea	0	0	1 (10.0)	0	1 (4.0)	0	0	0	2 (2.4)
Abdominal pain	0	0	0	0	1 (4.0)	0	0	1 (5.3)	2 (2.4)
Anemia	0	0	0	0	1 (4.0)	0	0	1 (5.3)	2 (2.4)
Vomiting	0	0	0	0	1 (4.0)	0	0	1 (5.3)	2 (2.4)
Tumor pain	1 (33.3)	0	1 (10.0)	0	0	0	0	0	2 (2.4)
Mucosal inflammation	0	0	0	0	0	0	0	2 (10.5)	2 (2.4)
Lipase increased	0	0	0	0	0	0	0	2 (10.5)	2 (2.4)
Cardiac tamponade	0	0	1 (10.0)	0	0	0	0	1 (5.3)	2 (2.4)
Gastrointestinal hemorrhage	0	0	0	0	2 (8.0)	0	0	0	2 (2.4)
Hypercalcemia	0	0	0	0	1 (4.0)	0	0	1 (5.3)	2 (2.4)
Hypophosphatemia	0	0	0	1 (14.3)	1 (4.0)	0	0	0	2 (2.4)

AE, adverse event; bid, twice daily; qd, once daily.